Clinical features of chronic hepatitis B in the presence of metabolic syndrome and insulin resistance
- Authors: Tkachenko LI1, Maleev VV2
-
Affiliations:
- ГБОУ ВПО "Ставропольский государственный медицинский университет" Минздрава России
- Центральный НИИ эпидемиологии Роспотребнадзора, Москва
- Issue: Vol 86, No 8 (2014)
- Pages: 18-22
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31528
- ID: 31528
Cite item
Full Text
Abstract
AIM. To assess the relationship of different components of metabolic syndrome (MS), viral load, and HBeAg status to the risk for cirrhosis of the liver in patients with chronic hepatitis B (CHB). MATERIALS AND METHODS. Fifty-three patients with CHB were examined according to the conventional criteria for patients with chronic hepatitis (the 2012 EASL guidelines). Analysis is made in relation to the degree of liver fibrosis (LF), the presence of MS, abdominal obesity, and insulin resistance (IR). RESULTS. MS was detected in 22.6% of the patients with CHB. The duration of the latter in MS was noted to be longer; the patients with MS were accordingly older than those without MS. The patients of this category were significantly more frequently observed to have type 2 diabetes mellitus (DM2), and IR, hepatic steatosis, and >3 METAVIR scores for LF, and elevated activity of hepatic enzymes (alanine aminotransferase, aspartate aminotransferase). Marked LF was associated with a high viral load, obesity, DM2, patient age, and MS. The patients with MS showed a higher activity of hepatic enzymes than those with abdominal obesity without MS. CONCLUSION. The percentage of CHB patients with MS increases with disease duration and patient age. High viral load, disease duration, MS, obesity, and DM2 are associated with score >3 METAVIR scores for significant LF.
Full Text
##article.viewOnOriginalSite##About the authors
L I Tkachenko
ГБОУ ВПО "Ставропольский государственный медицинский университет" Минздрава России
V V Maleev
Центральный НИИ эпидемиологии Роспотребнадзора, Москва
Email: maleyev@pcr.ru
References
- The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 2013; doi: 10.1016/S0140-6736(13)61836-X
- Schäffler A., Schölmerich J., Büchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue - emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 273-280.
- Kao J.H., Chen D.S. Overview of Hepatitis B and C virus. In Infectious cause of cancer: target for intervention. Ed. by: Guerdon T.J.J., Totowa N.J.: Humana press 2000: 313-330.
- Mari A., Ahren B., Pacini G. Assessments of insulin secretion in relation to insulin resistance. Curr Opin Clin Metab Care 2005; 8 (5): 529-533.
- Cindoruk M., Karakan T., Unal S. Hepatic Steatosis has no Impact on the Outcome of Treatment in Patients with Chronic Hepatitis B Infection. J Clin Gastroenterol 2007; 41 (5): 513-517.
- Федоров И.Г., Никитин И.Г., Сторожаков Г.И. Неалкогольный стеатогепатит: клиника, патогенез, диагностика, лечение. Consilium medicum 2004; 6 (6): 401-405.
- Adinolfi L.E., Gambardella M., Andreana A. et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
- Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis. Minerva Gastroenterol Dietol 2006; 52: 125-134.
- Yoon E.J., Ke-Qin Hu. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 2006; 3: 53-56.
- Poynard T., Ratziu V., McHutchison J. et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
- Moucari R., Asselah T., Cazals-Hatem D. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423.
- Антонова Т.В., Романова М.А., Сергеева Е.Г. Хронический гепатит С у больных с метаболическим синдромом. Журн инфектол 2011; 3: 91-96.
- Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39 (Suppl 1): S50-58.
- Tran T.T., Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis 2004; 8: 255-266.
- Chen C.J., Yang H.I., Su J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 1: 65-73.
- Iloeje U.H., Yang H.I., Su J. et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
- Chen G., Lin W.Y., Shen F.M. et al. Viral load as predictor of mortality from hepatocellular carcinoma and chronic liver disease in chronic hepatitis B infection. J Hepatol 2005; 42 (Suppl 2): 173.
- Гланц С. Медико-биологическая статистика: Пер. с англ. М: Практика1998; 459.
- Seung Ha Park, Dong Joon Kim, Heon Young Lee. Insulin Resistance Is Not Associated With Histologic Severity in Nondiabetic, Noncirrhotic Patients With Chronic Hepatitis B Virus Infection. Am J Gastroenterol 2009; 104: 1135-1139.
- Wong G.L.-H., Wong V.W.-S., Choi P.C.-L. et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-117.
![](/img/style/loading.gif)